Edition:
United States

MiMedx Group Inc (MDXG.OQ)

MDXG.OQ on NASDAQ Stock Exchange Capital Market

5.96USD
12:02pm EDT
Change (% chg)

$-0.02 (-0.33%)
Prev Close
$5.98
Open
$5.91
Day's High
$6.22
Day's Low
$5.87
Volume
136,236
Avg. Vol
967,166
52-wk High
$18.24
52-wk Low
$4.95

Latest Key Developments (Source: Significant Developments)

MiMedx Sees Q2 Revenue $96 Million To $98 Million
Thursday, 26 Apr 2018 08:30am EDT 

April 26 (Reuters) - MiMedx Group Inc ::MIMEDX REPORTS UNREVIEWED FIRST QUARTER REVENUE EXCEEDED UPPER END OF ITS GUIDANCE.SEES Q2 REVENUE $96 MILLION TO $98 MILLION.HAVE RAISED FULL YEAR REVENUE GUIDANCE TO A REVISED RANGE OF $389 MILLION TO $394 MILLION.MIMEDX GROUP - REAFFIRMED EXPECTATIONS FOR GROSS MARGIN, OPERATING INCOME, GAAP DILUTED EPS AND ADJUSTED DILUTED EPS FOR 2018.FY2018 EARNINGS PER SHARE VIEW $0.46, REVENUE VIEW $384.9 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

MiMedx Says "Confident" in Q1 Rev Guidance, Discloses DoJ Investigation
Thursday, 15 Mar 2018 10:40am EDT 

March 15 (Reuters) - MiMedx Group Inc ::MIMEDX ANNOUNCES EXPECTATION TO EXCEED THE $92 MILLION TOP END OF FIRST QUARTER REVENUE GUIDANCE.SEES FY 2018 REVENUE $383 MILLION TO $387 MILLION.SEES Q1 2018 REVENUE MORE THAN $92 MILLION.‍ RECENTLY INFORMED U.S. DOJ IS ALSO REVIEWING CO'S CERTAIN SALES AND DISTRIBUTION PRACTICES ON A PRELIMINARY BASIS​.‍CONTINUES TO PROVIDE DOCUMENTS IN RESPONSE TO SUBPOENA SERVED LAST YEAR BY SEC.  Full Article

Mimedx's Amniofix Injectable Granted RMAT Designation By FDA
Friday, 9 Mar 2018 12:45pm EST 

March 9 (Reuters) - Mimedx Group Inc ::AMNIOFIX INJECTABLE GRANTED REGENERATIVE MEDICINE ADVANCED THERAPY (RMAT) DESIGNATION BY THE FDA FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE.SAYS ‍FDA CONFIRMED DETERMINATION THAT MIMEDX ALLOGENEIC MICRONIZED DHACM FOR TREATMENT OF OA OF KNEE MEETS CRITERIA FOR RMAT DESIGNATION​.  Full Article

Mimedx Group Files For Non-Timely 10-K - SEC Filing
Friday, 2 Mar 2018 06:19am EST 

March 2 (Reuters) - Mimedx Group Inc ::MIMEDX GROUP FILES FOR NON-TIMELY 10-K - SEC FILING.MIMEDX - NOT ABLE TO PROVIDE QUANTITATIVE DESCRIPTION OF CHANGES IN RESULTS BETWEEN 2017, PRIOR PERIODS UNTIL AUDIT COMMITTEE COMPLETES INVESTIGATION.  Full Article

U.S. probes MiMedx's federal contracts, accounting - Bloomberg, Citing Sources
Monday, 26 Feb 2018 10:22am EST 

Feb 26 (Reuters) - :U.S. PROBES MIMEDX'S FEDERAL CONTRACTS, ACCOUNTING - BLOOMBERG, CITING SOURCES.  Full Article

MiMedx Postpones Release Of Fourth Quarter Results
Tuesday, 20 Feb 2018 08:41am EST 

Feb 20 (Reuters) - Mimedx Group Inc ::MIMEDX POSTPONES RELEASE OF ITS FOURTH QUARTER AND FISCAL YEAR 2017 FINANCIAL RESULTS.MIMEDX - ‍BOARD ENGAGED INDEPENDENT LEGAL AND ACCOUNTING ADVISORS TO CONDUCT AN INTERNAL INVESTIGATION INTO CURRENT & PRIOR-PERIOD MATTERS​.MIMEDX GROUP INC - ‍BOARD INVESTIGATION IS OF MATTERS RELATING TO ALLEGATIONS REGARDING CERTAIN SALES AND DISTRIBUTION PRACTICES AT COMPANY​.MIMEDX GROUP - BASED ON INFORMATION AVAILABLE TO DATE, OUTCOME OF INTERNAL INVESTIGATION SHOULD NOT HAVE MATERIAL IMPACT ON 2018 REVENUE GUIDANCE.MIMEDX GROUP INC - ‍COMPANY EXECUTIVES ARE ALSO REVIEWING, AMONG OTHER ITEMS, ACCOUNTING TREATMENT OF CERTAIN DISTRIBUTOR CONTRACTS​.MIMEDX GROUP - DOES NOT EXPECT DELAY IN RELEASE OF RESULTS TO AFFECT ITS OPERATIONAL PERFORMANCE AND CLINICAL RESEARCH ACTIVITIES.  Full Article

Mimedx Settles Patent Infringement Lawsuit
Thursday, 11 Jan 2018 02:45pm EST 

Jan 11 (Reuters) - Mimedx Group Inc ::MIMEDX - SUCCESSFULLY SETTLED CO'S PATENT INFRINGEMENT LAWSUIT AGAINST MUSCULOSKELETAL TRANSPLANT FOUNDATION, MEDLINE INDUSTRIES, LIVENTA BIOSCIENCE.MIMEDX - ‍HAS OBTAINED CONSENT DECREE AND FINAL JUDGMENT ON VALIDITY OF U.S. PATENT NO. 8,709,494​, AND WILL RECEIVE UNDISCLOSED MONETARY SUM.  Full Article

MiMedx Agrees To Lawsuit Settlement With Former Employee
Tuesday, 19 Dec 2017 08:00am EST 

Dec 19 (Reuters) - MiMedx Group Inc ::MIMEDX AGREES TO LAWSUIT SETTLEMENT WITH FORMER EMPLOYEE.MIMEDX GROUP INC - COMPANY HAS AGREED TO A CONFIDENTIAL LAWSUIT SETTLEMENT FROM ONE FORMER EMPLOYEE.MIMEDX GROUP INC - WILLIAM​ ‍MILLS HAS AGREED NOT TO SELL ANY PRODUCTS OF HIS CURRENT EMPLOYER TO ANY MIMEDX CUSTOMER SERVICED BY MILLS FOR NINE MONTHS.  Full Article

MiMedx Forecasts 2018 Revenue To Be In Range Of $383 Mln To $387 Mln
Wednesday, 13 Dec 2017 07:00am EST 

Dec 13 (Reuters) - MiMedx Group Inc ::MIMEDX FORECASTS 2018 REVENUE TO BE IN THE RANGE OF $383 MILLION TO $387 MILLION.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $0.45 TO $0.50 EXCLUDING ITEMS.SEES FY 2018 GAAP EARNINGS PER SHARE $0.30 TO $0.35.SEES FY 2018 REVENUE $383 MILLION TO $387 MILLION.FY2018 EARNINGS PER SHARE VIEW $0.43 -- THOMSON REUTERS I/B/E/S.  Full Article

MiMedx Says It Expects To Exceed Top End Of Q4 Revenue Guidance Of $88 Mln
Thursday, 30 Nov 2017 08:45am EST 

Nov 30 (Reuters) - Mimedx Group Inc ::MIMEDX ANNOUNCES EXPECTATION TO EXCEED TOP END OF FOURTH QUARTER REVENUE GUIDANCE OF $88 MILLION.SEES Q4 2017 REVENUE MORE THAN $88 MILLION.Q4 REVENUE VIEW $88.0 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

MiMedx to restate financial statements, replaces CFO

Biotech firm MiMedx Group Inc replaced its chief financial officer on Thursday and said it would restate at least five years of financial statements following an internal investigation into sales and distribution practices, sending shares down as much as 30 percent.